Guidance Before Reading
Critical Axes and Publication Biases
- Article Type: Prognosis. The topic is organized across five decision axes rather than a single global judgment.
- Evidence Base: High / Strong / Fully rated. 11 rated studies, of which 8 have high evidence weight.
- Bias Risk: Low to moderate. CoI Risk: Low. Source Integrity: clean.
- Core Thesis: Published survival rates are not synonymous with clinical success. The evaluation methodology changes the number by up to 14 percentage points.
Clinical Question
How reliable are published implant survival rates as a basis for patient education, and what methodological biases must be considered when interpreting them?
Executive Summary
The local body of literature includes 11 systematic reviews and meta-analyses and is strongly supportive for this topic. DDJ does not read the evidence as a single percentage, but rather organizes it along five clinical decision axes: endpoint definition, long-term analysis methodology, prosthetic complications, level of analysis, and educational standard. [1-11]
Published literature reports implant survival rates between 78% and 95%, depending on the endpoint, analysis method, and follow-up duration. This range is not a sign of uncertainty about the function of dental implants, but rather a reflection of methodological heterogeneity. [1,2]
The main direction is clear: Dental implants are an effective and long-term viable treatment. The critical question is not if, but how the results are communicated. The aggregated bias risk is low to moderate. The visible conclusion remains narrower than the raw topic name.
How DDJ Reads This Topic
Implantology is one of the most evidence-based fields in dentistry. Nevertheless, the way outcome numbers are reported leads to a systematic miscalibration of clinical expectations. DDJ treats this topic as a prognosis article: The fundamental efficacy is not in question, but rather the methodological honesty of the reporting. [1,2,4]
DDJ distinguishes five clinical axes, each with its own friction zones. Internal scores only control the evidence base. Visible are the clinical questions, conflict zones, and consequences.
Claim Clusters and Decision Axes
Claim Cluster 1 — ddj_0010_c01
Endpoint Definition: Survival vs. Success
Clinical Axis: Endpoint definition and result interpretation
Why this axis matters: Implant survival and implant success are fundamentally different clinical endpoints. Survival merely describes whether an implant is still in situ. Success additionally requires stable crestal bone, healthy periimplant tissues, and freedom from complications. Confusing or undifferentiated use of these endpoints leads to systematically overly positive outcome figures in published literature. [1,2]
Where the signal is stable: Padhye et al. (2023) show success rates ranging from 57.5% to 93.3% for the same material, depending on the definition of success used. This definitional heterogeneity is documented and replicated in the specialized literature. [2]
Where the uncertainty begins: In clinical practice and patient communication, both terms are often not separated. There is no international consensus for standardization.
Clinical implication: Every prognosis statement to the patient must name the endpoint used. A number without an endpoint definition is not information.
Claim Cluster 2 — ddj_0010_c02
20-Year Survival Rates and Analysis Methodology
Clinical Axis: Long-term survival rate and follow-up bias
Why this axis matters: After 20 years of follow-up time, the survival rate for screw-shaped titanium implants with a rough surface is between approximately 78% (after dropout imputation) and 88-92% (complete case or Kaplan-Meier analyses), depending on the analysis method. The discrepancy of up to 14 percentage points is a quantitative measure of the influence of follow-up losses on reported results. [1]
Where the signal is stable: Kupka et al. (2024) report in the first comprehensive 20-year meta-analysis: 92% for 237 prospectively followed implants, 88% in retrospective series (1440 implants), and 78% after imputation for lost cases (422 implants). [1]
Where the uncertainty begins: Which of the three numbers is communicated to the patient depends on the clinical situation and the methodology of the underlying study. The lowest number is not automatically the most honest—but neither is the highest.
Clinical implication: Published survival rates must be read with an indication of the analysis method and the dropout rate. Communicating only the Kaplan-Meier value omits a relevant dimension.